128 related articles for article (PubMed ID: 38578929)
1. Durability of the First Biologic in Children and Adults With Ulcerative Colitis: A Nationwide Study from the epi-IIRN.
Atia O; Friss C; Focht G; Magen Rimon R; Ledderman N; Greenfeld S; Ben-Tov A; Loewenberg Weisband Y; Matz E; Gorelik Y; Chowers Y; Dotan I; Turner D
Inflamm Bowel Dis; 2024 Apr; ():. PubMed ID: 38578929
[TBL] [Abstract][Full Text] [Related]
2. Durability of the First Biologic in Patients with Crohn's Disease: A Nationwide Study from the epi-IIRN.
Atia O; Friss C; Focht G; Magen Rimon R; Ledderman N; Greenfeld S; Ben-Tov A; Loewenberg Weisband Y; Matz E; Gorelik Y; Chowers Y; Dotan I; Turner D
J Crohns Colitis; 2024 Jan; 18(1):38-46. PubMed ID: 37465992
[TBL] [Abstract][Full Text] [Related]
3. Durability of Adalimumab and Infliximab in Children With Crohn's Disease: A Nationwide Comparison From the epi-IIRN Cohort.
Atia O; Friss C; Focht G; Magen Rimon R; Ledderman N; Ben-Tov A; Loewenberg Weisband Y; Matz E; Gorelik Y; Chowers Y; Dotan I; Turner D
Inflamm Bowel Dis; 2024 Jan; ():. PubMed ID: 38190498
[TBL] [Abstract][Full Text] [Related]
4. Comparative Long-Term Drug Survival of Vedolizumab, Adalimumab, and Infliximab in Biologic-Naïve Patients with Ulcerative Colitis.
Dalal RS; McClure EL; Marcus J; Allegretti JR
Dig Dis Sci; 2023 Jan; 68(1):223-232. PubMed ID: 35415826
[TBL] [Abstract][Full Text] [Related]
5. Drug utilization of biologic therapy in Crohn's disease and ulcerative colitis: a population-based Danish cohort study 2015-2020.
Jensen KJ; Jensen CB; Wennerström C; Burisch J; Petersen J
Scand J Gastroenterol; 2023 Jul; 58(7):726-736. PubMed ID: 36802972
[TBL] [Abstract][Full Text] [Related]
6. Prevalence and Outcomes of No Treatment Versus 5-ASA in Ulcerative Colitis: A Nationwide Analysis From the epi-IIRN.
Atia O; Magen Rimon R; Ledderman N; Greenfeld S; Kariv R; Loewenberg Weisband Y; Shaoul R; Matz E; Odes S; Goren I; Yanai H; Dotan I; Turner D
Inflamm Bowel Dis; 2024 Feb; 30(2):213-221. PubMed ID: 37084279
[TBL] [Abstract][Full Text] [Related]
7. Comparison of Infliximab and Adalimumab in Biologic-Naive Patients With Ulcerative Colitis: A Nationwide Danish Cohort Study.
Singh S; Andersen NN; Andersson M; Loftus EV; Jess T
Clin Gastroenterol Hepatol; 2017 Aug; 15(8):1218-1225.e7. PubMed ID: 27913244
[TBL] [Abstract][Full Text] [Related]
8. Subcutaneously Administered Anti-TNFs for the Treatment of Ulcerative Colitis: A Retrospective, Propensity Score-Matched, US Health Claims Analysis.
Stewart MJ; Bessissow T; Gregor J; Hazel M; In TSH; Karra K; Dajnowiec D; Williamson M; Sattin B
Adv Ther; 2021 Jul; 38(7):4115-4129. PubMed ID: 34159558
[TBL] [Abstract][Full Text] [Related]
9. The impact of biological interventions for ulcerative colitis on health-related quality of life.
LeBlanc K; Mosli MH; Parker CE; MacDonald JK
Cochrane Database Syst Rev; 2015 Sep; 2015(9):CD008655. PubMed ID: 26393522
[TBL] [Abstract][Full Text] [Related]
10. P074 Comparative Risk of Clostridioides Difficile Infection in Vedolizumab vs anti-TNFa Agents in Biologic-Naïve Patients With Ulcerative Colitis.
Dalal R; Mitri J; Goodrick H; Allegretti J
Am J Gastroenterol; 2021 Dec; 116(Suppl 1):S19. PubMed ID: 37461990
[TBL] [Abstract][Full Text] [Related]
11. Identification of the Most Cost-effective Position of Vedolizumab Among the Available Biologic Drugs for the Treatment of Ulcerative Colitis.
Scott FI; Luo M; Shah Y; Lasch K; Vajravelu RK; Mamtani R; Fennimore B; Gerich ME; Lewis JD
J Crohns Colitis; 2020 Jun; 14(5):575-587. PubMed ID: 31901085
[TBL] [Abstract][Full Text] [Related]
12. Budget Impact of Adding Vedolizumab to a Health Plan Formulary as Another First-Line Biologic Option for Ulcerative Colitis and Crohn's Disease.
Wilson M; Lucas A; Cameron A; Luo M
Am Health Drug Benefits; 2018 Jul; 11(5):253-262. PubMed ID: 30464793
[TBL] [Abstract][Full Text] [Related]
13. Treatment and biologic maintenance-dosing patterns among pediatric patients with ulcerative colitis or Crohn's disease.
Hunter T; Komocsar WJ; Colletti RB; Liu C; Benkov KJ; Dotson JL; Steiner SJ; Zhang N; Crandall W;
Curr Med Res Opin; 2023 Jan; 39(1):63-69. PubMed ID: 36263735
[TBL] [Abstract][Full Text] [Related]
14. Selection strategy of second-line biologic therapies in adult patients with ulcerative colitis following prior biologic treatment failure: Systematic review and meta-analysis.
Zhang H; Mu C; Gu Y; Meng F; Qin X; Cao H
Pharmacol Res; 2024 Apr; 202():107108. PubMed ID: 38403257
[TBL] [Abstract][Full Text] [Related]
15. Adalimumab or infliximab as monotherapy, or in combination with an immunomodulator, in the treatment of Crohn's disease.
Cosnes J; Sokol H; Bourrier A; Nion-Larmurier I; Wisniewski A; Landman C; Marteau P; Beaugerie L; Perez K; Seksik P
Aliment Pharmacol Ther; 2016 Nov; 44(10):1102-1113. PubMed ID: 27666569
[TBL] [Abstract][Full Text] [Related]
16. Real-World Persistence of Successive Biologics in Patients With Inflammatory Bowel Disease: Findings From ROTARY.
Krugliak Cleveland N; Ghosh S; Chastek B; Bancroft T; Candela N; Fan T; Umashankar K; Rubin DT
Inflamm Bowel Dis; 2023 Oct; ():. PubMed ID: 37921344
[TBL] [Abstract][Full Text] [Related]
17. Adalimumab, Infliximab, and Vedolizumab in Treatment of Ulcerative Colitis: A Long-Term Retrospective Study in a Tertiary Referral Center.
Gagnon AL; Beauchesne W; Tessier L; David C; Berbiche D; Lavoie A; Michaud-Herbst A; Tremblay K
Crohns Colitis 360; 2021 Oct; 3(4):otab049. PubMed ID: 36777273
[TBL] [Abstract][Full Text] [Related]
18. Trends in Medical Management of Moderately to Severely Active Ulcerative Colitis: A Nationwide Retrospective Analysis.
Yuan W; Marwaha JS; Rakowsky ST; Palmer NP; Kohane IS; Rubin DT; Brat GA; Feuerstein JD
Inflamm Bowel Dis; 2023 May; 29(5):695-704. PubMed ID: 35786768
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of intravenous vedolizumab vs subcutaneous adalimumab for moderately to severely active ulcerative colitis.
Schultz BG; Diakite I; Carter JA; Snedecor SJ; Turpin R
J Manag Care Spec Pharm; 2021 Nov; 27(11):1592-1600. PubMed ID: 34714104
[No Abstract] [Full Text] [Related]
20. Cost-effectiveness of vedolizumab compared with infliximab, adalimumab, and golimumab in patients with ulcerative colitis in the United Kingdom.
Wilson MR; Bergman A; Chevrou-Severac H; Selby R; Smyth M; Kerrigan MC
Eur J Health Econ; 2018 Mar; 19(2):229-240. PubMed ID: 28271250
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
